Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02834741 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability, PK of Oral NYX-2925 in Healthy Volunteers
A Phase 1 study, sponsored by Aptinyx.
- Completed
- Registry status
- Phase 1
- Development phase
- 84
- Enrollment target
NCT02834741 is a Phase 1 study that has completed, run by Aptinyx. The registered enrollment target is 84 participants.
The verdict
NCT02834741, a Phase 1 study, has completed, sponsored by Aptinyx.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 84 participants
- Enrollment target
Study Summary
This is a first in human study of NYX-2925. It will evaluate single and multiple ascending doses of NYX-2925 in healthy volunteers.
Interventions
- DRUG NYX-2925
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2016-07 |
| Est. Completion | 2017-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02834741
The ClinicalTrials.gov registry entry for NCT02834741 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 84 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aptinyx, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which NYX-2925 is the first listed.
NCT02834741 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02834741 about?
NCT02834741 is a clinical study titled "Safety, Tolerability, PK of Oral NYX-2925 in Healthy Volunteers". This is a first in human study of NYX-2925. It will evaluate single and multiple ascending doses of NYX-2925 in healthy volunteers.
What is the current status of trial NCT02834741?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 84 participants. The study started on 2016-07. Estimated completion is 2017-03.
What interventions are being tested in trial NCT02834741?
The interventions under investigation include: NYX-2925 (DRUG).
Who is sponsoring clinical trial NCT02834741?
This trial is sponsored by Aptinyx, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.